Filing Flows › Adma Biologics (ADMA) › Guidance history
Adma Biologics (ADMA) guidance history: what it guided and what it reported
Adma Biologics gave guidance in 3 earnings releases on file since May 6, 2026. Its releases raised guidance once and lowered it once.
Revenue
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $530M–$560M (May 6, 2026) → reaffirmed $530M–$560M (Aug 5, 2026) → lowered $530M (Nov 4, 2026) | — | to be reported | — |
Adjusted net income
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $170M–$200M (May 6, 2026) → reaffirmed $170M–$200M (Aug 5, 2026) → lowered $180M (Nov 4, 2026) | — | to be reported | — |
Adjusted EBITDA
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $265M–$300M (May 6, 2026) → reaffirmed $265M–$300M (Aug 5, 2026) → lowered $275M (Nov 4, 2026) | — | to be reported | — |
The latest quarter
Adma Biologics, Q3 2026: revenue $141M (+5% year over year), operating margin 48.0%, net earnings $49.9M, operating cash flow $17.4M. The chart follows the revenue to costs, profit and cash.
Questions
Does Adma Biologics beat its guidance?
Adma Biologics gave guidance in 3 earnings releases on file since May 6, 2026. Its releases raised guidance once and lowered it once.
How often does Adma Biologics raise guidance?
Its earnings releases raised guidance once and lowered it once since May 6, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.